This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Medullary carcinoma of the thyroid

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is a malignancy of the parafollicular cells of the thyroid.

This is a relatively uncommon thyroid carcinoma accounting for about 5% of thyroid malignancy. Both sexes are equally affected and the age of onset is variable. Aggressiveness is intermediate between that of well- differentiated and anaplastic lesions. About 80-90% of cases are sporadic; these usually affect adults and are unilateral. The other cases are familial, with an autosomal dominant inheritance; these tumours are typically bilateral and multifocal.

The medullary carcinoma arises from the parafollicular or C-cells of the thyroid which are of neural crest origin and form part of the APUD system. Calcitonin levels tend to be elevated and diagnostic. Levels of serum serotonin, ACTH and other peptides may also be raised. Spread to both regional lymph nodes and distant metastases to bone, liver and lung are common.

Diarrhoea and facial flushing are associated with medullary carcinomas of the thyroid.

20% of cases occur as part of the MEN-II syndrome.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.